<p>阿玛琳公司的最新财报电话会议展现了谨慎乐观的前景。公司报告称美国市场销售显著增长，得益于成功的合作伙伴关系和战略性成本削减。尽管这些积极的发展存在，但挑战依然存在，特别是来自其他地区市场的收入下降和持续的重组成本。</p>
<h2>总净收入增长</h2>
<p>2025 年第三季度，阿玛琳公司的总净收入上升至 4970 万美元，同比增长 17%。这一增长主要归因于美国市场销售的增加，展示了公司在国内市场的强劲表现。</p>
<h2>美国市场表现</h2>
<p>阿玛琳在美国的净产品收入激增至 4090 万美元，增长 34%。这一令人印象深刻的增长得益于净售价和销售量的增加，突显了公司有效的市场策略以及与主要药房福利管理者重新获得的独占权。</p>
<h2>与 Recordati 的成功合作</h2>
<p>与 Recordati 共同管理的欧洲全面合作商业模式的过渡进展顺利。该合作伙伴关系在所有商业化的欧洲市场中保持了需求的势头和增长，表明阿玛琳的战略举措取得了成功。</p>
<h2>成本节约与重组</h2>
<p>阿玛琳实现了显著的成本节约，销售和管理费用较去年减少了 47%。这一减少凸显了公司组织重组努力的好处，有助于其财务健康。</p>
<h2>FDA 对非诺贝特的标签更新</h2>
<p>FDA 最近对非诺贝特标签的修订，包括缺乏心血管益处的声明，预计将使临床实践转向像 VASCEPA 这样的有效疗法，可能提升其市场地位。</p>
<h2>其他地区收入下降</h2>
<p>尽管趋势积极，阿玛琳在其他地区的收入下降至 360 万美元。这一下降突显了公司在这些市场面临的变动性和挑战。</p>
<h2>欧洲收入稳定性</h2>
<p>欧洲产品收入保持在 410 万美元，与去年持平。然而，这一稳定性与美国市场的显著增长形成对比。</p>
<h2>持续的重组成本</h2>
<p>阿玛琳报告的重组费用为 940 万美元，导致运营亏损 1110 万美元。虽然预计这些成本在未来会减少，但目前仍对公司的财务表现产生影响。</p>
<h2>前瞻性指导</h2>
<p>展望未来，阿玛琳公司仍专注于全球扩展 VASCEPA 的市场覆盖，战略重点放在降低心血管风险上。公司预计到 2026 年实现正的自由现金流，得益于其成功的合作伙伴关系和运营成本节约。FDA 对非诺贝特的标签更新预计将进一步增强 VASCEPA 的市场吸引力。</p>
<p>总之，阿玛琳公司的财报电话会议揭示了积极的前景，得益于强劲的美国销售增长和战略合作伙伴关系。尽管国际市场仍面临挑战，但公司在成本削减和市场扩展方面的关注使其在未来成功的道路上处于良好位置。</p>

阿玛琳

<p>阿玛琳公司的财报电话会议强调了谨慎的乐观情绪，总净收入增长了 17%，达到 4970 万美元，主要得益于美国净产品收入增长 34%。该公司成功与 Recordati 合作进入欧洲市场，实现了显著的成本节约。然而，全球其他地区的收入下降以及 940 万美元的持续重组成本仍然是挑战，导致运营亏损 1110 万美元。展望未来，阿玛琳计划到 2026 年实现正现金流，重点扩大 VASCEPA 的市场覆盖，并受益于近期 FDA 标签更新</p>

<p>Amarin Corporation’s recent earnings call painted a picture of cautious optimism. The company reported significant growth in U.S. market sales, bolstered by successful partnerships and strategic cost reductions. Despite these positive developments, challenges persist, particularly with declining revenues from the Rest of World markets and ongoing restructuring costs.</p>
<div class="lb-trans"><p>阿玛琳公司的最新财报电话会议展现了谨慎乐观的前景。公司报告称美国市场销售显著增长，得益于成功的合作伙伴关系和战略性成本削减。尽管这些积极的发展存在，但挑战依然存在，特别是来自其他地区市场的收入下降和持续的重组成本。</p>
</div><h2>Increase in Total Net Revenue</h2>
<div class="lb-trans"><h2>总净收入增长</h2>
</div><p>The third quarter of 2025 saw Amarin Corporation’s total net revenue rise to $49.7 million, marking a 17% increase from the previous year. This growth was primarily attributed to higher sales in the U.S. market, showcasing the company’s strengthened domestic performance.</p>
<div class="lb-trans"><p>2025 年第三季度，阿玛琳公司的总净收入上升至 4970 万美元，同比增长 17%。这一增长主要归因于美国市场销售的增加，展示了公司在国内市场的强劲表现。</p>
</div><h2>U.S. Market Performance</h2>
<div class="lb-trans"><h2>美国市场表现</h2>
</div><p>Amarin’s U.S. net product revenue surged to $40.9 million, reflecting a 34% increase. This impressive growth was driven by an increase in both net selling price and sales volume, highlighting the company’s effective market strategies and regained exclusivity with a major pharmacy benefit manager.</p>
<div class="lb-trans"><p>阿玛琳在美国的净产品收入激增至 4090 万美元，增长 34%。这一令人印象深刻的增长得益于净售价和销售量的增加，突显了公司有效的市场策略以及与主要药房福利管理者重新获得的独占权。</p>
</div><h2>Successful Partnership with Recordati</h2>
<div class="lb-trans"><h2>与 Recordati 的成功合作</h2>
</div><p>The transition to a fully partnered commercial model in Europe, managed by Recordati, is progressing well. This partnership has maintained momentum and growth in demand across all commercialized European markets, indicating a successful strategic move by Amarin.</p>
<div class="lb-trans"><p>与 Recordati 共同管理的欧洲全面合作商业模式的过渡进展顺利。该合作伙伴关系在所有商业化的欧洲市场中保持了需求的势头和增长，表明阿玛琳的战略举措取得了成功。</p>
</div><h2>Cost Savings and Restructuring</h2>
<div class="lb-trans"><h2>成本节约与重组</h2>
</div><p>Amarin achieved significant cost savings, reducing SG&amp;A expenses by 47% compared to the previous year. This reduction underscores the benefits of the company’s organizational restructuring efforts, contributing to its financial health.</p>
<div class="lb-trans"><p>阿玛琳实现了显著的成本节约，销售和管理费用较去年减少了 47%。这一减少凸显了公司组织重组努力的好处，有助于其财务健康。</p>
</div><h2>FDA Labeling Update on Fenofibrates</h2>
<div class="lb-trans"><h2>FDA 对非诺贝特的标签更新</h2>
</div><p>The FDA’s recent revision of fenofibrates labeling to include a statement on the lack of cardiovascular benefit is expected to shift clinical practices towards proven therapies like VASCEPA, potentially boosting its market position.</p>
<div class="lb-trans"><p>FDA 最近对非诺贝特标签的修订，包括缺乏心血管益处的声明，预计将使临床实践转向像 VASCEPA 这样的有效疗法，可能提升其市场地位。</p>
</div><h2>Decline in Rest of World Revenue</h2>
<div class="lb-trans"><h2>其他地区收入下降</h2>
</div><p>Despite the positive trends, Amarin faced a decline in Rest of World revenue, which fell to $3.6 million. This decline highlights the variability and challenges the company faces in these markets.</p>
<div class="lb-trans"><p>尽管趋势积极，阿玛琳在其他地区的收入下降至 360 万美元。这一下降突显了公司在这些市场面临的变动性和挑战。</p>
</div><h2>European Revenue Consistency</h2>
<div class="lb-trans"><h2>欧洲收入稳定性</h2>
</div><p>European product revenue remained stable at $4.1 million, consistent with the previous year. However, this stability contrasts with the significant growth seen in the U.S. market.</p>
<div class="lb-trans"><p>欧洲产品收入保持在 410 万美元，与去年持平。然而，这一稳定性与美国市场的显著增长形成对比。</p>
</div><h2>Ongoing Restructuring Costs</h2>
<div class="lb-trans"><h2>持续的重组成本</h2>
</div><p>Amarin reported restructuring expenses of $9.4 million, contributing to an operating loss of $11.1 million. While these costs are expected to decrease in the future, they currently impact the company’s financial performance.</p>
<div class="lb-trans"><p>阿玛琳报告的重组费用为 940 万美元，导致运营亏损 1110 万美元。虽然预计这些成本在未来会减少，但目前仍对公司的财务表现产生影响。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Looking ahead, Amarin Corporation remains focused on expanding VASCEPA’s market reach globally, with a strategic emphasis on cardiovascular risk reduction. The company anticipates achieving positive free cash flow by 2026, supported by its successful partnerships and operational cost savings. The FDA’s labeling update on fenofibrates is expected to further enhance VASCEPA’s market appeal.</p>
<div class="lb-trans"><p>展望未来，阿玛琳公司仍专注于全球扩展 VASCEPA 的市场覆盖，战略重点放在降低心血管风险上。公司预计到 2026 年实现正的自由现金流，得益于其成功的合作伙伴关系和运营成本节约。FDA 对非诺贝特的标签更新预计将进一步增强 VASCEPA 的市场吸引力。</p>
</div><p>In summary, Amarin Corporation’s earnings call revealed a positive outlook, driven by robust U.S. sales growth and strategic partnerships. While challenges remain, particularly in international markets, the company’s focus on cost reduction and market expansion positions it well for future success.</p>
<div class="lb-trans"><p>总之，阿玛琳公司的财报电话会议揭示了积极的前景，得益于强劲的美国销售增长和战略合作伙伴关系。尽管国际市场仍面临挑战，但公司在成本削减和市场扩展方面的关注使其在未来成功的道路上处于良好位置。</p>
</div>

阿玛琳公司在财报电话会议中强调了其增长和面临的挑战